Comparative analysis and isoform-specific therapeutic vulnerabilities of KRAS mutations in non-small cell lung cancer.

Activating missense mutations of KRAS are the most frequent oncogenic driver events in lung adenocarcinoma (LUAD). However, KRAS isoforms are highly heterogeneous, and data on the potential isoform-dependent therapeutic vulnerabilities are still lacking.We developed an isogenic cell-based platform to compare the oncogenic properties and specific therapeutic actionability of KRAS mutant isoforms. In parallel, we analyzed clinicopathologic and genomic data from 3560 patients with non-small cell lung cancer (NSCLC) to survey allele-specific features associated with oncogenic KRAS mutations.In isogenic cell lines expressing different mutant KRAS isoforms, we identified isoform-specific biochemical, biological and oncogenic properties both in vitro and in vivo These exclusive features correlated with different therapeutic responses to MEK inhibitors, with KRAS G12C and Q61H mutants being more sensitive compared to other isoforms. In vivo, combined KRAS G12C and MEK inhibition was more effective than either drug alone. Among patients with NSCLCs which underwent comprehensive tumor genomic profiling, STK11 and ATM mutations were significantly enriched among tumors harboring KRAS G12C, G12A, and G12V mutations. KEAP1 mutation was significantly enriched among KRAS G12C and KRAS G13X LUADs. KRAS G13X mutated tumors had the highest frequency of concurrent STK11 and KEAP1 mutations. Transcriptomic profiling revealed unique patterns of gene expression in each KRAS isoform, compared to KRAS wild-type tumors.This study demonstrates that KRAS isoforms are highly heterogeneous in terms of concurrent genomic alterations and gene expression profiles, and that stratification based on KRAS alleles should be considered in the design of future clinical trials.